{"gene":"APOA4","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":1986,"finding":"The human APOA4 gene contains only two introns (unlike APOA1 and APOC3 which have three), with introns separating sequences encoding the signal peptide and amphipathic domains, establishing that APOA1, APOC3, and APOA4 genes share a common evolutionary ancestor and that APOA4 lost one ancestral intron during evolution.","method":"Gene isolation, restriction mapping, and intron/exon structure analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct gene characterization with structural analysis, single study, foundational genomic work but limited functional mechanistic follow-up","pmids":["3095836"],"is_preprint":false},{"year":2021,"finding":"LRP1 (low-density lipoprotein receptor-related protein 1) was identified as a cognate receptor for APOA4 in adipose tissue; LRP1 co-localizes with APOA4 in adipocytes, their interaction is enhanced during lipid feeding, and knockdown of LRP1 abrogated APOA4-induced glucose uptake and PI3K/AKT activation in 3T3-L1 adipocytes.","method":"Co-immunoprecipitation coupled with mass spectrometry, co-localization imaging, siRNA knockdown, glucose uptake assay, western blot for PI3K/AKT","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP/MS identification, co-localization, siRNA rescue experiment, multiple orthogonal methods in single study","pmids":["34168225"],"is_preprint":false},{"year":2019,"finding":"ApoA4 functions as a sphingosine 1-phosphate (S1P) chaperone: recombinant ApoA4 bound S1P directly, activated multiple S1P receptors, and promoted vascular endothelial barrier function, substituting for ApoM and albumin as an S1P chaperone in double-knockout mice.","method":"Recombinant protein S1P binding assay, S1P receptor activation assays, endothelial barrier function assay, ApoM/albumin double-knockout mouse model","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of S1P binding and receptor activation, in vivo genetic model, multiple orthogonal functional assays","pmids":["31462513"],"is_preprint":false},{"year":2017,"finding":"ApoA4 stimulates SERPINA3 gene expression in mouse hepatocytes via transcriptional regulation mediated by binding of nuclear receptors NR4A1 and NR1D1 to the SERPINA3 promoter, establishing a mechanism for ApoA4's anti-inflammatory effects.","method":"ChIP assay, luciferase reporter assay, RNA interference (NR4A1/NR1D1 knockdown), in vivo and in vitro dose/time-dependent expression analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase reporter with siRNA validation, multiple orthogonal methods, single laboratory","pmids":["28412351"],"is_preprint":false},{"year":2011,"finding":"ApoA4 is a target gene of the transcription factor LUMAN (CREB3/LZIP) in dendritic cells; constitutively active LUMAN induced ApoA4 expression, confirmed by promoter analysis and silencing studies.","method":"Microarray analysis, bioinformatics promoter analysis, LUMAN overexpression, gene silencing in DC cell line and bone marrow-derived DCs","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — overexpression and silencing with promoter validation, multiple methods, single laboratory","pmids":["22209087"],"is_preprint":false},{"year":2015,"finding":"ApoA4 exhibited inferior lipid-binding and LCAT activation compared to ApoA-I; in lipid-free state ApoA4 multimerized up to dimer while ApoA-I pentamerized; ApoA4-rHDL showed less LCAT activation and ApoA4 inhibited acetylated LDL uptake only in lipid-free (not lipid-bound) state, indicating structural and functional differences from ApoA-I.","method":"Native gel electrophoresis, BS3 crosslinking, reconstituted HDL formation assay, LCAT activation assay, acetylated LDL uptake inhibition assay","journal":"Molecules and cells","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — multiple in vitro biochemical assays with reconstituted protein, single laboratory","pmids":["25997739"],"is_preprint":false},{"year":2021,"finding":"APOA4 expression in the liver is induced by hepatocyte growth factor (HGF) in a c-Met-dependent manner; rh-HGF administration upregulated hepatic APOA4 mRNA and protein in mice and primary human hepatocytes, and this induction was blocked by a c-Met inhibitor.","method":"In vivo rh-HGF administration to mice, primary cultured human hepatocytes, c-Met inhibitor treatment, mRNA and protein quantification, serum APOA4 measurement in acute liver failure model","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro validation with pharmacological inhibitor, two model systems, single laboratory","pmids":["33925510"],"is_preprint":false},{"year":2023,"finding":"Two missense mutations in APOA4 (p.L66V and p.D33N) cause autosomal dominant medullary amyloidosis with chronic kidney disease; mutated ApoA4 was identified by mass spectrometry as the predominant amyloid constituent in kidney biopsies, and both mutations are predicted to expand the amyloidogenic hotspot in ApoA4 structure.","method":"Whole genome sequencing, clinical genetics, kidney biopsy with amyloid staining, mass spectrometry identification of amyloid protein, plasma ApoA4 measurement","journal":"Kidney international","confidence":"High","confidence_rationale":"Tier 2 / Strong — mass spectrometry confirmation of amyloid composition in multiple biopsies, replicated across five families, two distinct pathogenic variants","pmids":["38096951"],"is_preprint":false},{"year":2025,"finding":"CD300LG acts as a receptor for triglyceride-rich lipoproteins (TRLs) through a direct interaction with ApoA4, facilitating TRL clearance at the microvascular endothelium; this interaction was identified mechanistically in a study of postprandial lipid clearance.","method":"Direct protein interaction assay, mouse CD300LG deficiency model, human genetic analysis, postprandial lipid clearance assay","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct interaction identified with in vivo genetic model, preprint not yet peer-reviewed, single study","pmids":["bio_10.1101_2025.08.08.669356"],"is_preprint":true},{"year":2025,"finding":"TMAO upregulates hepatic PCSK9 expression and reduces APOA4 expression; PCSK9 knockdown increases APOA4 expression and APOA4 overexpression reduces PCSK9 expression, establishing a reciprocal regulatory feedback loop between PCSK9 and APOA4 in hepatocyte cholesterol metabolism.","method":"siRNA knockdown, overexpression plasmids in AML12 hepatocytes, RNA sequencing, ELISA, murine TMAO-induced cholelithiasis model","journal":"Journal of clinical and translational hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal knockdown/overexpression experiments in vitro and in vivo, multiple orthogonal methods, single laboratory","pmids":["40206272"],"is_preprint":false},{"year":2022,"finding":"ApoA4 deficiency in mice leads to expansion of specific inflammatory macrophage subsets (Cxcl9+ and Cxcl2+ macrophages) and activated granulocytes (Wfdc17+) in the liver, with increased NE and IL-1β expression, demonstrating that ApoA4 suppresses hepatic innate immune cell activation and inflammatory signaling (including Nr4a1 reduction) in NAFLD.","method":"Single-cell RNA sequencing of liver immune cells from WT and ApoA4-deficient mice on high-fat diet, immunostaining, qRT-PCR validation","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — scRNA-seq with immunostaining validation, KO mouse model with defined cellular phenotype, single laboratory","pmids":["36426356"],"is_preprint":false},{"year":2026,"finding":"APOA4 protects chondrocytes by upregulating anabolic ECM markers (COL2, ACAN), downregulating catabolic factors (MMP3, MMP13), attenuating IL-1β-induced inflammation, and suppressing Wnt/β-catenin signaling; Wnt3a treatment partially reversed these chondroprotective effects.","method":"Recombinant APOA4 treatment, siRNA knockdown, overexpression in human chondrocytes (C28/I2), RNA-seq, CCK-8 proliferation assay, IL-1β inflammatory model, Wnt3a rescue experiment, qPCR, ELISA","journal":"Journal of inflammation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro methods with rescue experiment, single laboratory, newly published","pmids":["42147793"],"is_preprint":false}],"current_model":"APOA4 is a multifunctional apolipoprotein that facilitates lipid transport (including as a chaperone for sphingosine 1-phosphate), promotes glucose uptake in adipose tissue via its receptor LRP1 through PI3K/AKT activation, interacts directly with CD300LG at the microvascular endothelium to facilitate clearance of triglyceride-rich lipoproteins, regulates hepatic inflammation by suppressing innate immune cell activation, transcriptionally induces SERPINA3 via nuclear receptors NR4A1/NR1D1, participates in a reciprocal regulatory loop with PCSK9 in cholesterol metabolism, is induced in the liver by HGF in a c-Met-dependent manner, and is transcriptionally activated by the LUMAN/CREB3 transcription factor in dendritic cells; pathogenic missense mutations (p.L66V, p.D33N) cause autosomal dominant medullary amyloidosis with chronic kidney disease."},"narrative":{"mechanistic_narrative":"APOA4 is a multifunctional apolipoprotein that links lipid transport to metabolic and immune regulation across the liver, vasculature, and adipose tissue [PMID:31462513, PMID:34168225, PMID:36426356]. As a lipid carrier it binds and transports the bioactive lipid sphingosine 1-phosphate, activating S1P receptors and supporting vascular endothelial barrier function in place of ApoM and albumin [PMID:31462513], while in its lipid-free versus lipid-bound states it exhibits distinct multimerization and weaker LCAT activation and lipid-binding behavior than ApoA-I [PMID:25997739]. At the cell surface APOA4 engages defined receptors to drive metabolic signaling: it binds LRP1 in adipocytes to stimulate glucose uptake through PI3K/AKT activation [PMID:34168225] and interacts directly with CD300LG at the microvascular endothelium to promote clearance of triglyceride-rich lipoproteins [PMID:bio_10.1101_2025.08.08.669356]. APOA4 also functions as a regulator of inflammation, suppressing hepatic innate immune cell activation in NAFLD [PMID:36426356] and acting through nuclear receptors NR4A1 and NR1D1 to transcriptionally induce the anti-inflammatory gene SERPINA3 [PMID:28412351]. Its own hepatic expression is controlled by HGF/c-Met signaling [PMID:33925510] and a reciprocal regulatory loop with PCSK9 in cholesterol metabolism [PMID:40206272]. Pathogenic missense mutations p.L66V and p.D33N render APOA4 itself the predominant amyloid constituent in autosomal dominant medullary amyloidosis with chronic kidney disease [PMID:38096951].","teleology":[{"year":1986,"claim":"Establishing the gene's intron/exon architecture answered whether APOA4 is evolutionarily related to other apolipoproteins, placing it in a shared ancestral lineage with APOA1 and APOC3.","evidence":"Gene isolation, restriction mapping, and intron/exon structure analysis of the human APOA4 locus","pmids":["3095836"],"confidence":"Medium","gaps":["No functional or mechanistic role assigned to the encoded protein","Structure-function consequences of intron loss not addressed"]},{"year":2017,"claim":"Identifying NR4A1/NR1D1-mediated induction of SERPINA3 provided a transcriptional mechanism for how APOA4 exerts anti-inflammatory effects in hepatocytes.","evidence":"ChIP, luciferase reporter, and NR4A1/NR1D1 siRNA in mouse hepatocytes with in vivo/in vitro expression analysis","pmids":["28412351"],"confidence":"Medium","gaps":["How extracellular APOA4 signals to nuclear receptors is unresolved","Single laboratory, mouse hepatocyte system"]},{"year":2019,"claim":"Demonstrating direct S1P binding and receptor activation established APOA4 as a bona fide S1P chaperone capable of supporting endothelial barrier function, extending its role beyond classical lipid transport.","evidence":"Recombinant protein S1P binding, S1P receptor activation, endothelial barrier assays, and ApoM/albumin double-knockout mice","pmids":["31462513"],"confidence":"High","gaps":["Physiological contribution relative to ApoM in normal animals not quantified","S1P-binding residues not mapped"]},{"year":2021,"claim":"Identifying LRP1 as a cognate receptor explained how APOA4 triggers intracellular glucose-uptake signaling in adipose tissue.","evidence":"Co-IP/MS, co-localization, LRP1 siRNA knockdown, glucose uptake and PI3K/AKT readouts in 3T3-L1 adipocytes","pmids":["34168225"],"confidence":"High","gaps":["In vivo confirmation of LRP1-dependent glucose uptake not established","Binding interface and stoichiometry undefined"]},{"year":2021,"claim":"Linking hepatic APOA4 induction to HGF/c-Met signaling identified an upstream growth-factor pathway controlling APOA4 expression in liver injury.","evidence":"rh-HGF administration in mice and primary human hepatocytes with c-Met inhibitor blockade and serum APOA4 measurement","pmids":["33925510"],"confidence":"Medium","gaps":["Transcription factors downstream of c-Met driving APOA4 not identified","Functional consequence of HGF-induced APOA4 unclear"]},{"year":2022,"claim":"Single-cell profiling of ApoA4-deficient livers resolved which immune cell populations APOA4 restrains, defining its suppressive role over inflammatory macrophages and granulocytes in NAFLD.","evidence":"scRNA-seq of liver immune cells from WT and ApoA4-KO mice on high-fat diet with immunostaining and qRT-PCR validation","pmids":["36426356"],"confidence":"Medium","gaps":["Direct versus indirect action of APOA4 on immune cells not separated","Receptor mediating immune suppression not identified"]},{"year":2023,"claim":"Mapping p.L66V and p.D33N to medullary amyloidosis established APOA4 itself as a causative amyloidogenic protein in an inherited kidney disease.","evidence":"Whole genome sequencing, clinical genetics across five families, and mass spectrometry of amyloid in kidney biopsies","pmids":["38096951"],"confidence":"High","gaps":["Mechanism by which mutations promote fibrillization not experimentally demonstrated","Why deposition is medullary/kidney-specific unexplained"]},{"year":2025,"claim":"Defining the reciprocal PCSK9–APOA4 loop showed APOA4 participates in a feedback circuit governing hepatocyte cholesterol metabolism.","evidence":"siRNA/overexpression in AML12 hepatocytes, RNA-seq, ELISA, and a murine TMAO-induced cholelithiasis model","pmids":["40206272"],"confidence":"Medium","gaps":["Molecular intermediary of the reciprocal regulation unknown","Whether regulation is transcriptional or post-translational unresolved"]},{"year":2025,"claim":"Identifying a direct APOA4–CD300LG interaction provided an endothelial receptor mechanism for postprandial triglyceride-rich lipoprotein clearance.","evidence":"Direct protein interaction assay, CD300LG-deficient mice, human genetics, and postprandial lipid clearance (preprint)","pmids":["bio_10.1101_2025.08.08.669356"],"confidence":"Medium","gaps":["Preprint, not yet peer-reviewed","Binding interface and downstream uptake machinery undefined"]},{"year":2026,"claim":"Demonstrating APOA4 chondroprotection via Wnt/β-catenin suppression extended its anti-inflammatory and tissue-protective role to cartilage.","evidence":"Recombinant APOA4, siRNA, overexpression in C28/I2 chondrocytes with IL-1β model and Wnt3a rescue","pmids":["42147793"],"confidence":"Medium","gaps":["Receptor mediating chondrocyte effects not identified","In vivo cartilage relevance not tested"]},{"year":null,"claim":"How APOA4's distinct receptor engagements (LRP1, CD300LG, S1P receptors) and transcriptional circuits are coordinated into a unified physiological program, and how missense mutations convert it into an amyloidogenic protein, remain open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking lipid/receptor binding to amyloid propensity","Tissue-specific receptor usage not integrated","Causal in vivo hierarchy among the regulatory loops unestablished"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,5]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[1,2,8]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,7]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,9]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,10]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,6]}],"complexes":[],"partners":["LRP1","CD300LG","PCSK9","NR4A1","NR1D1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P06727","full_name":"Apolipoprotein A-IV","aliases":["Apolipoprotein A4"],"length_aa":396,"mass_kda":45.4,"function":"May have a role in chylomicrons and VLDL secretion and catabolism. Required for efficient activation of lipoprotein lipase by ApoC-II; potent activator of LCAT. Apoa-IV is a major component of HDL and chylomicrons","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P06727/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOA4","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOA4","total_profiled":1310},"omim":[{"mim_id":"621106","title":"TUBULOINTERSTITIAL KIDNEY DISEASE, AUTOSOMAL DOMINANT 6; ADTKD6","url":"https://www.omim.org/entry/621106"},{"mim_id":"620112","title":"APOA1 ANTISENSE RNA, NONCODING; APOA1AS","url":"https://www.omim.org/entry/620112"},{"mim_id":"620058","title":"FAMILIAL APOLIPOPROTEIN GENE CLUSTER DELETION SYNDROME","url":"https://www.omim.org/entry/620058"},{"mim_id":"611998","title":"cAMP RESPONSE ELEMENT-BINDING PROTEIN 3-LIKE 3; CREB3L3","url":"https://www.omim.org/entry/611998"},{"mim_id":"606945","title":"LOW DENSITY LIPOPROTEIN RECEPTOR; LDLR","url":"https://www.omim.org/entry/606945"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":2929.9}],"url":"https://www.proteinatlas.org/search/APOA4"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P06727","domains":[{"cath_id":"1.20.120.20","chopping":"180-359","consensus_level":"medium","plddt":87.725,"start":180,"end":359}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P06727","model_url":"https://alphafold.ebi.ac.uk/files/AF-P06727-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P06727-F1-predicted_aligned_error_v6.png","plddt_mean":80.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOA4","jax_strain_url":"https://www.jax.org/strain/search?query=APOA4"},"sequence":{"accession":"P06727","fasta_url":"https://rest.uniprot.org/uniprotkb/P06727.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P06727/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P06727"}},"corpus_meta":[{"pmid":"3095836","id":"PMC_3095836","title":"Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4).","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3095836","citation_count":81,"is_preprint":false},{"pmid":"2903847","id":"PMC_2903847","title":"DNA polymorphism haplotypes of the human apolipoprotein APOA1-APOC3-APOA4 gene cluster.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2903847","citation_count":70,"is_preprint":false},{"pmid":"27131369","id":"PMC_27131369","title":"A long non-coding RNA, APOA4-AS, regulates APOA4 expression depending on HuR in mice.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27131369","citation_count":67,"is_preprint":false},{"pmid":"26491253","id":"PMC_26491253","title":"Decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with risk of Alzheimer's disease.","date":"2015","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26491253","citation_count":45,"is_preprint":false},{"pmid":"12556235","id":"PMC_12556235","title":"The study of APOA1, APOC3 and APOA4 variability in healthy ageing people reveals another paradox in the oldest old subjects.","date":"2003","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12556235","citation_count":42,"is_preprint":false},{"pmid":"34168225","id":"PMC_34168225","title":"Low-density lipoprotein receptor-related protein 1 (LRP1) is a novel receptor for apolipoprotein A4 (APOA4) in adipose tissue.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34168225","citation_count":41,"is_preprint":false},{"pmid":"31462513","id":"PMC_31462513","title":"Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice.","date":"2019","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/31462513","citation_count":40,"is_preprint":false},{"pmid":"21407247","id":"PMC_21407247","title":"Effect of walnut-enriched meat on the relationship between VCAM, ICAM, and LTB4 levels and PON-1 activity in ApoA4 360 and PON-1 allele carriers at increased cardiovascular risk.","date":"2011","source":"European journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/21407247","citation_count":37,"is_preprint":false},{"pmid":"26824674","id":"PMC_26824674","title":"Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26824674","citation_count":34,"is_preprint":false},{"pmid":"28412351","id":"PMC_28412351","title":"Effect of ApoA4 on SERPINA3 mediated by nuclear receptors NR4A1 and NR1D1 in hepatocytes.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28412351","citation_count":28,"is_preprint":false},{"pmid":"8838914","id":"PMC_8838914","title":"Population distributions of APOE, APOH, and APOA4 polymorphisms and their relationships with quantitative plasma lipid levels among the Evenki herders of Siberia.","date":"1996","source":"Human biology","url":"https://pubmed.ncbi.nlm.nih.gov/8838914","citation_count":25,"is_preprint":false},{"pmid":"20164363","id":"PMC_20164363","title":"APOA1 and APOA4 gene polymorphisms influence the effects of dietary fat on LDL particle size and oxidation in healthy young adults.","date":"2010","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/20164363","citation_count":24,"is_preprint":false},{"pmid":"29675916","id":"PMC_29675916","title":"Serum ApoA4 levels predicted the progression of renal impairment in T2DM.","date":"2018","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29675916","citation_count":21,"is_preprint":false},{"pmid":"22209087","id":"PMC_22209087","title":"Analysis of genes regulated by the transcription factor LUMAN identifies ApoA4 as a target gene in dendritic cells.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22209087","citation_count":21,"is_preprint":false},{"pmid":"26397108","id":"PMC_26397108","title":"Effects of Polymorphisms in APOA4-APOA5-ZNF259-BUD13 Gene Cluster on Plasma Levels of Triglycerides and Risk of Coronary Heart Disease in a Chinese Han Population.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26397108","citation_count":20,"is_preprint":false},{"pmid":"21712729","id":"PMC_21712729","title":"APOA4 polymorphism as a risk factor for unfavorable lipid serum profile and depression: a cross-sectional study.","date":"2011","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/21712729","citation_count":19,"is_preprint":false},{"pmid":"36426356","id":"PMC_36426356","title":"Single-cell RNA sequencing reveals a novel inhibitory effect of ApoA4 on NAFL mediated by liver-specific subsets of myeloid cells.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36426356","citation_count":14,"is_preprint":false},{"pmid":"37357772","id":"PMC_37357772","title":"HDL anti-inflammatory function is impaired and associated with high SAA1 and low APOA4 levels in aneurysmal subarachnoid hemorrhage.","date":"2023","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37357772","citation_count":13,"is_preprint":false},{"pmid":"38096951","id":"PMC_38096951","title":"Autosomal dominant ApoA4 mutations present as tubulointerstitial kidney disease with medullary amyloidosis.","date":"2023","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/38096951","citation_count":12,"is_preprint":false},{"pmid":"25997739","id":"PMC_25997739","title":"Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity.","date":"2015","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/25997739","citation_count":11,"is_preprint":false},{"pmid":"31607136","id":"PMC_31607136","title":"The significance of calprotectin, CD147, APOA4 and DJ-1 in non-invasive detection of urinary bladder carcinoma.","date":"2019","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/31607136","citation_count":10,"is_preprint":false},{"pmid":"31181149","id":"PMC_31181149","title":"Interaction of polymorphisms in APOA4-APOA5-ZPR1-BUD13 gene cluster and sleep duration on 5-year lipid changes in middle aged and older Chinese.","date":"2019","source":"Sleep","url":"https://pubmed.ncbi.nlm.nih.gov/31181149","citation_count":8,"is_preprint":false},{"pmid":"23096082","id":"PMC_23096082","title":"Minor allele of the APOA4 gene T347S polymorphism predisposes to obesity in postmenopausal Turkish women.","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23096082","citation_count":8,"is_preprint":false},{"pmid":"40206272","id":"PMC_40206272","title":"PCSK9 and APOA4: The Dynamic Duo in TMAO-induced Cholesterol Metabolism and Cholelithiasis.","date":"2025","source":"Journal of clinical and translational hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/40206272","citation_count":6,"is_preprint":false},{"pmid":"34938775","id":"PMC_34938775","title":"The Variants at APOA1 and APOA4 Contribute to the Susceptibility of Schizophrenia With Inhibiting mRNA Expression in Peripheral Blood Leukocytes.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34938775","citation_count":6,"is_preprint":false},{"pmid":"26485402","id":"PMC_26485402","title":"Transcriptome Reveals 1400-Fold Upregulation of APOA4-APOC3 and 1100-Fold Downregulation of GIF in the Patients with Polycythemia-Induced Gastric Injury.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26485402","citation_count":6,"is_preprint":false},{"pmid":"33403595","id":"PMC_33403595","title":"Depression Augments Plasma APOA4 without Changes of Plasma Lipids and Glucose in Female Adolescents Carrying G Allele of APOA4 rs5104.","date":"2021","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/33403595","citation_count":5,"is_preprint":false},{"pmid":"1427832","id":"PMC_1427832","title":"Linkage heterogeneity between the C3 and LDLR and the APOA4 and APOA1 loci in baboons.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1427832","citation_count":5,"is_preprint":false},{"pmid":"33925510","id":"PMC_33925510","title":"Serum APOA4 Pharmacodynamically Represents Administered Recombinant Human Hepatocyte Growth Factor (E3112).","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33925510","citation_count":3,"is_preprint":false},{"pmid":"27622441","id":"PMC_27622441","title":"LEP, LDLR and APOA4 gene polymorphisms and their relationship with the risk of overweight, obesity and chronic diseases in adults of the State of Sucre, Venezuela.","date":"2016","source":"Biomedica : revista del Instituto Nacional de Salud","url":"https://pubmed.ncbi.nlm.nih.gov/27622441","citation_count":3,"is_preprint":false},{"pmid":"39566154","id":"PMC_39566154","title":"Miniaturized 3D-printed ratiometric electrochemical immunosensing platform for ultrasensitive detection of depression biomarker Apo-A4.","date":"2024","source":"Talanta","url":"https://pubmed.ncbi.nlm.nih.gov/39566154","citation_count":3,"is_preprint":false},{"pmid":"2894008","id":"PMC_2894008","title":"NcoI dimorphic site located 8kb 3' to the human apolipoprotein AIV (APOA4) gene.","date":"1988","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2894008","citation_count":3,"is_preprint":false},{"pmid":"39569650","id":"PMC_39569650","title":"Therapeutic potential of simvastatin in ALS: Enhanced axonal integrity and motor neuron survival through Apoa4 and Alb modulation.","date":"2025","source":"Biomolecules & biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39569650","citation_count":2,"is_preprint":false},{"pmid":"39916324","id":"PMC_39916324","title":"Establishment and characterization of liver-specific Apoa4-Cre and Cyp2c11-Cre rat models in juvenile and adult stages.","date":"2025","source":"Animal models and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39916324","citation_count":1,"is_preprint":false},{"pmid":"40665476","id":"PMC_40665476","title":"Genome-wide study links cardiometabolic factors to cognition via APOA4-APOA5-ZPR1-BUD13 and other loci in rural Indians.","date":"2025","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/40665476","citation_count":1,"is_preprint":false},{"pmid":"42147793","id":"PMC_42147793","title":"APOA4 Protects Chondrocytes and Modulates Wnt Signaling in Osteoarthritis.","date":"2026","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/42147793","citation_count":0,"is_preprint":false},{"pmid":"41684813","id":"PMC_41684813","title":"Wharton's jelly mesenchymal stem cell-secretome enhances skin rejuvenation via ApoA4 and SERPINH1.","date":"2026","source":"Regenerative therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41684813","citation_count":0,"is_preprint":false},{"pmid":"41582167","id":"PMC_41582167","title":"Predictive value of serum apolipoprotein panel (ApoA1 / ApoA2 / ApoA4) as a biomarker for individual radiosensitivity.","date":"2026","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/41582167","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.08.669356","title":"CD300LG is a receptor for triglyceride-rich lipoproteins that facilitates postprandial lipid clearance","date":"2025-08-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.08.669356","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.23.619940","title":"A genotype-phenotype transformer to assess and explain polygenic risk","date":"2024-10-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.23.619940","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.01.24318258","title":"Extreme MetaboHealth scores in three cohort studies associate with plasma protein markers for inflammation and cholesterol transport","date":"2024-12-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.01.24318258","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24692,"output_tokens":3101,"usd":0.060296,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10561,"output_tokens":3398,"usd":0.068877,"stage2_stop_reason":"end_turn"},"total_usd":0.129173,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"The human APOA4 gene contains only two introns (unlike APOA1 and APOC3 which have three), with introns separating sequences encoding the signal peptide and amphipathic domains, establishing that APOA1, APOC3, and APOA4 genes share a common evolutionary ancestor and that APOA4 lost one ancestral intron during evolution.\",\n      \"method\": \"Gene isolation, restriction mapping, and intron/exon structure analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct gene characterization with structural analysis, single study, foundational genomic work but limited functional mechanistic follow-up\",\n      \"pmids\": [\"3095836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LRP1 (low-density lipoprotein receptor-related protein 1) was identified as a cognate receptor for APOA4 in adipose tissue; LRP1 co-localizes with APOA4 in adipocytes, their interaction is enhanced during lipid feeding, and knockdown of LRP1 abrogated APOA4-induced glucose uptake and PI3K/AKT activation in 3T3-L1 adipocytes.\",\n      \"method\": \"Co-immunoprecipitation coupled with mass spectrometry, co-localization imaging, siRNA knockdown, glucose uptake assay, western blot for PI3K/AKT\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP/MS identification, co-localization, siRNA rescue experiment, multiple orthogonal methods in single study\",\n      \"pmids\": [\"34168225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ApoA4 functions as a sphingosine 1-phosphate (S1P) chaperone: recombinant ApoA4 bound S1P directly, activated multiple S1P receptors, and promoted vascular endothelial barrier function, substituting for ApoM and albumin as an S1P chaperone in double-knockout mice.\",\n      \"method\": \"Recombinant protein S1P binding assay, S1P receptor activation assays, endothelial barrier function assay, ApoM/albumin double-knockout mouse model\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of S1P binding and receptor activation, in vivo genetic model, multiple orthogonal functional assays\",\n      \"pmids\": [\"31462513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ApoA4 stimulates SERPINA3 gene expression in mouse hepatocytes via transcriptional regulation mediated by binding of nuclear receptors NR4A1 and NR1D1 to the SERPINA3 promoter, establishing a mechanism for ApoA4's anti-inflammatory effects.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, RNA interference (NR4A1/NR1D1 knockdown), in vivo and in vitro dose/time-dependent expression analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase reporter with siRNA validation, multiple orthogonal methods, single laboratory\",\n      \"pmids\": [\"28412351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ApoA4 is a target gene of the transcription factor LUMAN (CREB3/LZIP) in dendritic cells; constitutively active LUMAN induced ApoA4 expression, confirmed by promoter analysis and silencing studies.\",\n      \"method\": \"Microarray analysis, bioinformatics promoter analysis, LUMAN overexpression, gene silencing in DC cell line and bone marrow-derived DCs\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — overexpression and silencing with promoter validation, multiple methods, single laboratory\",\n      \"pmids\": [\"22209087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ApoA4 exhibited inferior lipid-binding and LCAT activation compared to ApoA-I; in lipid-free state ApoA4 multimerized up to dimer while ApoA-I pentamerized; ApoA4-rHDL showed less LCAT activation and ApoA4 inhibited acetylated LDL uptake only in lipid-free (not lipid-bound) state, indicating structural and functional differences from ApoA-I.\",\n      \"method\": \"Native gel electrophoresis, BS3 crosslinking, reconstituted HDL formation assay, LCAT activation assay, acetylated LDL uptake inhibition assay\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple in vitro biochemical assays with reconstituted protein, single laboratory\",\n      \"pmids\": [\"25997739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"APOA4 expression in the liver is induced by hepatocyte growth factor (HGF) in a c-Met-dependent manner; rh-HGF administration upregulated hepatic APOA4 mRNA and protein in mice and primary human hepatocytes, and this induction was blocked by a c-Met inhibitor.\",\n      \"method\": \"In vivo rh-HGF administration to mice, primary cultured human hepatocytes, c-Met inhibitor treatment, mRNA and protein quantification, serum APOA4 measurement in acute liver failure model\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro validation with pharmacological inhibitor, two model systems, single laboratory\",\n      \"pmids\": [\"33925510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Two missense mutations in APOA4 (p.L66V and p.D33N) cause autosomal dominant medullary amyloidosis with chronic kidney disease; mutated ApoA4 was identified by mass spectrometry as the predominant amyloid constituent in kidney biopsies, and both mutations are predicted to expand the amyloidogenic hotspot in ApoA4 structure.\",\n      \"method\": \"Whole genome sequencing, clinical genetics, kidney biopsy with amyloid staining, mass spectrometry identification of amyloid protein, plasma ApoA4 measurement\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mass spectrometry confirmation of amyloid composition in multiple biopsies, replicated across five families, two distinct pathogenic variants\",\n      \"pmids\": [\"38096951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CD300LG acts as a receptor for triglyceride-rich lipoproteins (TRLs) through a direct interaction with ApoA4, facilitating TRL clearance at the microvascular endothelium; this interaction was identified mechanistically in a study of postprandial lipid clearance.\",\n      \"method\": \"Direct protein interaction assay, mouse CD300LG deficiency model, human genetic analysis, postprandial lipid clearance assay\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct interaction identified with in vivo genetic model, preprint not yet peer-reviewed, single study\",\n      \"pmids\": [\"bio_10.1101_2025.08.08.669356\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TMAO upregulates hepatic PCSK9 expression and reduces APOA4 expression; PCSK9 knockdown increases APOA4 expression and APOA4 overexpression reduces PCSK9 expression, establishing a reciprocal regulatory feedback loop between PCSK9 and APOA4 in hepatocyte cholesterol metabolism.\",\n      \"method\": \"siRNA knockdown, overexpression plasmids in AML12 hepatocytes, RNA sequencing, ELISA, murine TMAO-induced cholelithiasis model\",\n      \"journal\": \"Journal of clinical and translational hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal knockdown/overexpression experiments in vitro and in vivo, multiple orthogonal methods, single laboratory\",\n      \"pmids\": [\"40206272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ApoA4 deficiency in mice leads to expansion of specific inflammatory macrophage subsets (Cxcl9+ and Cxcl2+ macrophages) and activated granulocytes (Wfdc17+) in the liver, with increased NE and IL-1β expression, demonstrating that ApoA4 suppresses hepatic innate immune cell activation and inflammatory signaling (including Nr4a1 reduction) in NAFLD.\",\n      \"method\": \"Single-cell RNA sequencing of liver immune cells from WT and ApoA4-deficient mice on high-fat diet, immunostaining, qRT-PCR validation\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — scRNA-seq with immunostaining validation, KO mouse model with defined cellular phenotype, single laboratory\",\n      \"pmids\": [\"36426356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"APOA4 protects chondrocytes by upregulating anabolic ECM markers (COL2, ACAN), downregulating catabolic factors (MMP3, MMP13), attenuating IL-1β-induced inflammation, and suppressing Wnt/β-catenin signaling; Wnt3a treatment partially reversed these chondroprotective effects.\",\n      \"method\": \"Recombinant APOA4 treatment, siRNA knockdown, overexpression in human chondrocytes (C28/I2), RNA-seq, CCK-8 proliferation assay, IL-1β inflammatory model, Wnt3a rescue experiment, qPCR, ELISA\",\n      \"journal\": \"Journal of inflammation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro methods with rescue experiment, single laboratory, newly published\",\n      \"pmids\": [\"42147793\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOA4 is a multifunctional apolipoprotein that facilitates lipid transport (including as a chaperone for sphingosine 1-phosphate), promotes glucose uptake in adipose tissue via its receptor LRP1 through PI3K/AKT activation, interacts directly with CD300LG at the microvascular endothelium to facilitate clearance of triglyceride-rich lipoproteins, regulates hepatic inflammation by suppressing innate immune cell activation, transcriptionally induces SERPINA3 via nuclear receptors NR4A1/NR1D1, participates in a reciprocal regulatory loop with PCSK9 in cholesterol metabolism, is induced in the liver by HGF in a c-Met-dependent manner, and is transcriptionally activated by the LUMAN/CREB3 transcription factor in dendritic cells; pathogenic missense mutations (p.L66V, p.D33N) cause autosomal dominant medullary amyloidosis with chronic kidney disease.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"APOA4 is a multifunctional apolipoprotein that links lipid transport to metabolic and immune regulation across the liver, vasculature, and adipose tissue [#2, #1, #10]. As a lipid carrier it binds and transports the bioactive lipid sphingosine 1-phosphate, activating S1P receptors and supporting vascular endothelial barrier function in place of ApoM and albumin [#2], while in its lipid-free versus lipid-bound states it exhibits distinct multimerization and weaker LCAT activation and lipid-binding behavior than ApoA-I [#5]. At the cell surface APOA4 engages defined receptors to drive metabolic signaling: it binds LRP1 in adipocytes to stimulate glucose uptake through PI3K/AKT activation [#1] and interacts directly with CD300LG at the microvascular endothelium to promote clearance of triglyceride-rich lipoproteins [#8]. APOA4 also functions as a regulator of inflammation, suppressing hepatic innate immune cell activation in NAFLD [#10] and acting through nuclear receptors NR4A1 and NR1D1 to transcriptionally induce the anti-inflammatory gene SERPINA3 [#3]. Its own hepatic expression is controlled by HGF/c-Met signaling [#6] and a reciprocal regulatory loop with PCSK9 in cholesterol metabolism [#9]. Pathogenic missense mutations p.L66V and p.D33N render APOA4 itself the predominant amyloid constituent in autosomal dominant medullary amyloidosis with chronic kidney disease [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Establishing the gene's intron/exon architecture answered whether APOA4 is evolutionarily related to other apolipoproteins, placing it in a shared ancestral lineage with APOA1 and APOC3.\",\n      \"evidence\": \"Gene isolation, restriction mapping, and intron/exon structure analysis of the human APOA4 locus\",\n      \"pmids\": [\"3095836\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional or mechanistic role assigned to the encoded protein\", \"Structure-function consequences of intron loss not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identifying NR4A1/NR1D1-mediated induction of SERPINA3 provided a transcriptional mechanism for how APOA4 exerts anti-inflammatory effects in hepatocytes.\",\n      \"evidence\": \"ChIP, luciferase reporter, and NR4A1/NR1D1 siRNA in mouse hepatocytes with in vivo/in vitro expression analysis\",\n      \"pmids\": [\"28412351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How extracellular APOA4 signals to nuclear receptors is unresolved\", \"Single laboratory, mouse hepatocyte system\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating direct S1P binding and receptor activation established APOA4 as a bona fide S1P chaperone capable of supporting endothelial barrier function, extending its role beyond classical lipid transport.\",\n      \"evidence\": \"Recombinant protein S1P binding, S1P receptor activation, endothelial barrier assays, and ApoM/albumin double-knockout mice\",\n      \"pmids\": [\"31462513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological contribution relative to ApoM in normal animals not quantified\", \"S1P-binding residues not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying LRP1 as a cognate receptor explained how APOA4 triggers intracellular glucose-uptake signaling in adipose tissue.\",\n      \"evidence\": \"Co-IP/MS, co-localization, LRP1 siRNA knockdown, glucose uptake and PI3K/AKT readouts in 3T3-L1 adipocytes\",\n      \"pmids\": [\"34168225\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo confirmation of LRP1-dependent glucose uptake not established\", \"Binding interface and stoichiometry undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linking hepatic APOA4 induction to HGF/c-Met signaling identified an upstream growth-factor pathway controlling APOA4 expression in liver injury.\",\n      \"evidence\": \"rh-HGF administration in mice and primary human hepatocytes with c-Met inhibitor blockade and serum APOA4 measurement\",\n      \"pmids\": [\"33925510\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factors downstream of c-Met driving APOA4 not identified\", \"Functional consequence of HGF-induced APOA4 unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Single-cell profiling of ApoA4-deficient livers resolved which immune cell populations APOA4 restrains, defining its suppressive role over inflammatory macrophages and granulocytes in NAFLD.\",\n      \"evidence\": \"scRNA-seq of liver immune cells from WT and ApoA4-KO mice on high-fat diet with immunostaining and qRT-PCR validation\",\n      \"pmids\": [\"36426356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect action of APOA4 on immune cells not separated\", \"Receptor mediating immune suppression not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mapping p.L66V and p.D33N to medullary amyloidosis established APOA4 itself as a causative amyloidogenic protein in an inherited kidney disease.\",\n      \"evidence\": \"Whole genome sequencing, clinical genetics across five families, and mass spectrometry of amyloid in kidney biopsies\",\n      \"pmids\": [\"38096951\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which mutations promote fibrillization not experimentally demonstrated\", \"Why deposition is medullary/kidney-specific unexplained\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defining the reciprocal PCSK9–APOA4 loop showed APOA4 participates in a feedback circuit governing hepatocyte cholesterol metabolism.\",\n      \"evidence\": \"siRNA/overexpression in AML12 hepatocytes, RNA-seq, ELISA, and a murine TMAO-induced cholelithiasis model\",\n      \"pmids\": [\"40206272\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular intermediary of the reciprocal regulation unknown\", \"Whether regulation is transcriptional or post-translational unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying a direct APOA4–CD300LG interaction provided an endothelial receptor mechanism for postprandial triglyceride-rich lipoprotein clearance.\",\n      \"evidence\": \"Direct protein interaction assay, CD300LG-deficient mice, human genetics, and postprandial lipid clearance (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.08.08.669356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not yet peer-reviewed\", \"Binding interface and downstream uptake machinery undefined\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Demonstrating APOA4 chondroprotection via Wnt/β-catenin suppression extended its anti-inflammatory and tissue-protective role to cartilage.\",\n      \"evidence\": \"Recombinant APOA4, siRNA, overexpression in C28/I2 chondrocytes with IL-1β model and Wnt3a rescue\",\n      \"pmids\": [\"42147793\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating chondrocyte effects not identified\", \"In vivo cartilage relevance not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How APOA4's distinct receptor engagements (LRP1, CD300LG, S1P receptors) and transcriptional circuits are coordinated into a unified physiological program, and how missense mutations convert it into an amyloidogenic protein, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking lipid/receptor binding to amyloid propensity\", \"Tissue-specific receptor usage not integrated\", \"Causal in vivo hierarchy among the regulatory loops unestablished\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 5]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 2, 8]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 10]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LRP1\", \"CD300LG\", \"PCSK9\", \"NR4A1\", \"NR1D1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}